180 related articles for article (PubMed ID: 25427433)
1. Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children.
Ruangwattanapaisarn N; Hsiao A; Vasanawala SS
Pediatr Radiol; 2015 Jun; 45(6):831-9. PubMed ID: 25427433
[TBL] [Abstract][Full Text] [Related]
2. Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol.
Luhar A; Khan S; Finn JP; Ghahremani S; Griggs R; Zaritsky J; Salusky I; Hall TR
Pediatr Radiol; 2016 Aug; 46(9):1332-40. PubMed ID: 27059620
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic safety and efficacy of ferumoxytol as an intravenous contrast agents in pediatric patients and young adults.
Ning P; Zucker EJ; Wong P; Vasanawala SS
Magn Reson Imaging; 2016 Feb; 34(2):152-8. PubMed ID: 26518061
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of ferumoxytol-enhanced neonatal and young infant cardiac MRI without general anesthesia.
Lai LM; Cheng JY; Alley MT; Zhang T; Lustig M; Vasanawala SS
J Magn Reson Imaging; 2017 May; 45(5):1407-1418. PubMed ID: 27678106
[TBL] [Abstract][Full Text] [Related]
5. High-resolution three‑dimensional contrast‑enhanced magnetic resonance venography in children: comparison of gadofosveset trisodium with ferumoxytol.
Shahrouki P; Khan SN; Yoshida T; Iskander PJ; Ghahremani S; Finn JP
Pediatr Radiol; 2022 Mar; 52(3):501-512. PubMed ID: 34936018
[TBL] [Abstract][Full Text] [Related]
6. Ferumoxytol magnetic resonance angiography: a dose-finding study in patients with chronic kidney disease.
Stoumpos S; Hennessy M; Vesey AT; Radjenovic A; Kasthuri R; Kingsmore DB; Mark PB; Roditi G
Eur Radiol; 2019 Jul; 29(7):3543-3552. PubMed ID: 30919067
[TBL] [Abstract][Full Text] [Related]
7. Ferumoxytol enhanced black-blood cardiovascular magnetic resonance imaging.
Nguyen KL; Park EA; Yoshida T; Hu P; Finn JP
J Cardiovasc Magn Reson; 2017 Dec; 19(1):106. PubMed ID: 29284494
[TBL] [Abstract][Full Text] [Related]
8. High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort.
Nayak AB; Luhar A; Hanudel M; Gales B; Hall TR; Finn JP; Salusky IB; Zaritsky J
Pediatr Nephrol; 2015 Mar; 30(3):515-21. PubMed ID: 25212105
[TBL] [Abstract][Full Text] [Related]
9. Brand ferumoxytol vs. generic ferumoxytol comparison across two dosing regimens: a cardiac MRI image quality study.
Dasi A; Kring DN; Selvaraj B; Morgan P; Gerity C; Morgan EE; Krishnamurthy R; Krishnamurthy R
Pediatr Radiol; 2023 Dec; 53(13):2622-2632. PubMed ID: 37837456
[TBL] [Abstract][Full Text] [Related]
10. Ferumoxytol use as an intravenous contrast agent for magnetic resonance angiography.
Stabi KL; Bendz LM
Ann Pharmacother; 2011 Dec; 45(12):1571-5. PubMed ID: 22045905
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of ultrasmall superparamagnetic iron-oxide (USPIO) enhanced MRI with ferumoxytol to quantify arterial wall inflammation.
Smits LP; Tiessens F; Zheng KH; Stroes ES; Nederveen AJ; Coolen BF
Atherosclerosis; 2017 Aug; 263():211-218. PubMed ID: 28662398
[TBL] [Abstract][Full Text] [Related]
12. High resolution, 3-dimensional Ferumoxytol-enhanced cardiovascular magnetic resonance venography in central venous occlusion.
Shahrouki P; Moriarty JM; Khan SN; Bista B; Kee ST; DeRubertis BG; Yoshida T; Nguyen KL; Finn JP
J Cardiovasc Magn Reson; 2019 Mar; 21(1):17. PubMed ID: 30853026
[TBL] [Abstract][Full Text] [Related]
13. First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent.
Li W; Tutton S; Vu AT; Pierchala L; Li BS; Lewis JM; Prasad PV; Edelman RR
J Magn Reson Imaging; 2005 Jan; 21(1):46-52. PubMed ID: 15611942
[TBL] [Abstract][Full Text] [Related]
14. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study.
Neuwelt EA; Várallyay CG; Manninger S; Solymosi D; Haluska M; Hunt MA; Nesbit G; Stevens A; Jerosch-Herold M; Jacobs PM; Hoffman JM
Neurosurgery; 2007 Apr; 60(4):601-11; discussion 611-2. PubMed ID: 17415196
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary MRA During Pregnancy: Early Experience With Ferumoxytol.
Starekova J; Nagle SK; Schiebler ML; Reeder SB; Meduri VN
J Magn Reson Imaging; 2023 Jun; 57(6):1815-1818. PubMed ID: 36315131
[TBL] [Abstract][Full Text] [Related]
16. High-resolution 3D volumetric contrast-enhanced MR angiography with a blood pool agent (ferumoxytol) for diagnostic evaluation of pediatric brain arteriovenous malformations.
Iv M; Choudhri O; Dodd RL; Vasanawala SS; Alley MT; Moseley M; Holdsworth SJ; Grant G; Cheshier S; Yeom KW
J Neurosurg Pediatr; 2018 Sep; 22(3):251-260. PubMed ID: 29882734
[TBL] [Abstract][Full Text] [Related]
17. Combined blood pool and extracellular contrast agents for pediatric and young adult cardiovascular magnetic resonance imaging.
Johnson JT; Robinson JD; Deng J; Rigsby CK
Pediatr Radiol; 2016 Dec; 46(13):1822-1830. PubMed ID: 27576457
[TBL] [Abstract][Full Text] [Related]
18. Safety of ferumoxytol in children undergoing cardiac MRI under general anaesthesia.
Wise-Faberowski L; Velasquez N; Chan F; Vasanawala S; McElhinney DB; Ramamoorthy C
Cardiol Young; 2018 Jul; 28(7):916-921. PubMed ID: 29848399
[TBL] [Abstract][Full Text] [Related]
19. Ferumoxytol-enhanced magnetic resonance angiography is a feasible method for the clinical evaluation of lower extremity arterial disease.
Walker JP; Nosova E; Sigovan M; Rapp J; Grenon MS; Owens CD; Gasper WJ; Saloner DA
Ann Vasc Surg; 2015 Jan; 29(1):63-8. PubMed ID: 25269682
[TBL] [Abstract][Full Text] [Related]
20. Crossover comparison of ferumoxytol and gadobenate dimeglumine for abdominal MR-angiography at 3.0 tesla: Effects of contrast bolus length and flip angle.
Schubert T; Motosugi U; Kinner S; Colgan TJ; Sharma SD; Hetzel S; Wells S; Campo CA; Reeder SB
J Magn Reson Imaging; 2017 Jun; 45(6):1617-1626. PubMed ID: 27862577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
